Wells Fargo
TXG icon

Wells Fargo’s 10x Genomics TXG Stock Holding History

Wells Fargo’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97M Sell
140,116
-204,834
-59% -$4.09M ﹤0.01% 2979
2025
Q4 		$5.63M Buy
344,950
+102,791
+42% +$1.55M ﹤0.01% 2561
2025
Q3 		$2.83M Buy
242,159
+177,485
+274% +$2.31M ﹤0.01% 3066
2025
Q2 		$749K Buy
64,674
+63,535
+5,578% +$579K ﹤0.01% 3877
2025
Q1 		$9.94K Sell
1,139
-254
-18% -$3.2K ﹤0.01% 5882
2024
Q4 		$20K Sell
1,393
-10,535
-88% -$166K ﹤0.01% 5769
2024
Q3 		$269K Buy
11,928
+2,196
+23% +$45.4K ﹤0.01% 4383
2024
Q2 		$189K Sell
9,732
-7,423
-43% -$194K ﹤0.01% 4549
2024
Q1 		$644K Sell
17,155
-9,512
-36% -$418K ﹤0.01% 3725
2023
Q4 		$1.49M Sell
26,667
-11,989
-31% -$522K ﹤0.01% 3133
2023
Q3 		$1.59M Sell
38,656
-6,429
-14% -$334K ﹤0.01% 2969
2023
Q2 		$2.52M Buy
45,085
+7,418
+20% +$401K ﹤0.01% 2717
2023
Q1 		$2.1M Sell
37,667
-33,414
-47% -$1.56M ﹤0.01% 2816
2022
Q4 		$2.59M Sell
71,081
-18,571
-21% -$607K ﹤0.01% 2576
2022
Q3 		$2.55M Sell
89,652
-39,390
-31% -$1.5M ﹤0.01% 2535
2022
Q2 		$5.84M Sell
129,042
-118,646
-48% -$6.16M ﹤0.01% 1972
2022
Q1 		$18.8M Buy
247,688
+54,217
+28% +$4.74M ﹤0.01% 1349
2021
Q4 		$28.8M Sell
193,471
-598,229
-76% -$91.6M 0.01% 1089
2021
Q3 		$115M Buy
791,700
+23,753
+3% +$4.08M 0.03% 591
2021
Q2 		$150M Buy
767,947
+8,574
+1% +$1.55M 0.03% 487
2021
Q1 		$137M Buy
759,373
+706,619
+1,339% +$122M 0.03% 519
2020
Q4 		$7.47M Buy
52,754
+19,293
+58% +$2.8M ﹤0.01% 2357
2020
Q3 		$4.17M Sell
33,461
-230,034
-87% -$24.1M ﹤0.01% 2677
2020
Q2 		$23.5M Sell
263,495
-511,359
-66% -$39.8M 0.01% 1260
2020
Q1 		$48.3M Sell
774,854
-152,908
-16% -$11.9M 0.02% 776
2019
Q4 		$70.7M Buy
927,762
+12,324
+1% +$741K 0.02% 750
2019
Q3 		$46.1M Buy
+915,438
New +$50.7M 0.01% 956

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's TXG Position: Q1 2026 in Review

Wells Fargo reduced its 10x Genomics (TXG) stake by 59% in Q1 2026, selling an estimated $4.09M and leaving 140,116 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

Wells Fargo first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $150M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Wells Fargo held 140,116 shares of 10x Genomics worth $2.97M as of Q1 2026.
  • Wells Fargo sold 204,834 10x Genomics shares in Q1 2026, an estimated $4.09M.
  • 10x Genomics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2979 holding.
  • Wells Fargo first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • Wells Fargo's 10x Genomics position peaked at $150M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.